

Florian Franz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/554374/publications.pdf>

Version: 2024-02-01

22
papers

930
citations

471061

17
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

776
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. <i>Analytical Chemistry</i> , 2016, 88, 11476-11485.	3.2	193
2	Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. <i>Analytical Chemistry</i> , 2017, 89, 9527-9536.	3.2	81
3	Detection of the recently emerged synthetic cannabinoid 5F- <i>MDMB-PICA</i> in "legal high"™ products and human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 196-205.	1.6	78
4	Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. <i>Forensic Toxicology</i> , 2015, 33, 388-395.	1.4	58
5	Phase I metabolism of the highly potent synthetic cannabinoid <i>MDMB-CHMICA</i> and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2017, 9, 744-753.	1.6	54
6	Adverse effects after the use of <i>JWH-210</i> – a case series from the EU Spice II plus project. <i>Drug Testing and Analysis</i> , 2016, 8, 1030-1038.	1.6	47
7	Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1375-1384.	1.4	46
8	Acute side effects after consumption of the new synthetic cannabinoids <i>AB-CHMINACA</i> and <i>MDMB-CHMICA</i> . <i>Clinical Toxicology</i> , 2018, 56, 404-411.	0.8	46
9	Metabolites of synthetic cannabinoids in hair – proof of consumption or false friends for interpretation?. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 3445-3452.	1.9	45
10	Characterization and <i>in vitro</i> phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. <i>Journal of Mass Spectrometry</i> , 2016, 51, 1080-1089.	0.7	38
11	Reply to "Sudden Cardiac Death Following Use of the Synthetic Cannabinoid <i>MDMB-CHMICA</i> ". <i>Journal of Analytical Toxicology</i> , 2016, 40, 240-242.	1.7	30
12	Synthetic cannabinoids in hair – Pragmatic approach for method updates, compound prevalences and concentration ranges in authentic hair samples. <i>Analytica Chimica Acta</i> , 2018, 1006, 61-73.	2.6	30
13	Phase I metabolism of the recently emerged synthetic cannabinoid <i>CUMYL-PEGACLONE</i> and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 886-891.	1.6	28
14	<i>5F-Cumyl-PINACA</i> in "e-liquids"™ for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of <i>5F-Cumyl-PINACA</i> and its non-fluorinated analog <i>Cumyl-PINACA</i> . <i>Forensic Toxicology</i> , 2019, 37, 186-196.	1.4	28
15	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2019, 37, 316-329.	1.4	24
16	Detection and phase I metabolism of the <i>7-azaindole</i> -derived synthetic cannabinoid <i>5F-AB-P7AICA</i> including a preliminary pharmacokinetic evaluation. <i>Drug Testing and Analysis</i> , 2020, 12, 78-91.	1.6	21
17	<i>In vitro</i> metabolism of the synthetic cannabinoid <i>3,5-AB-CHMFUPPYCA</i> and its 5,3-regioisomer and investigation of their thermal stability. <i>Drug Testing and Analysis</i> , 2017, 9, 311-316.	1.6	19
18	Human phase I metabolism of the novel synthetic cannabinoid <i>5F-CUMYL-PEGACLONE</i> . <i>Forensic Toxicology</i> , 2019, 37, 154-163.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCA and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 1417-1429.	1.6	15
20	Metabolism of Nine Synthetic Cannabinoid Receptor Agonists Encountered in Clinical Casework: Major in vivo Phase I Metabolites of AM-694, AM-2201, JWH-007, JWH-019, JWH-203, JWH-307, MAM-2201, UR-144 and XLR-11 in Human Urine Using LC-MS/MS. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 144-162.	0.9	14
21	Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine – Potential impact on therapeutic decisions. <i>Drug Testing and Analysis</i> , 2020, 12, 391-396.	1.6	10
22	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. <i>International Journal of Legal Medicine</i> , 2019, 133, 1049-1064.	1.2	8